A Phase II Study of TAS-102 in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
Price : $35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 30 Jan 2019 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.
- 30 Jan 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Jul 2021.
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.